Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03273153
Registration number
NCT03273153
Ethics application status
Date submitted
1/09/2017
Date registered
6/09/2017
Date last updated
21/09/2022
Titles & IDs
Public title
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Query!
Scientific title
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Query!
Secondary ID [1]
0
0
2016-004387-18
Query!
Secondary ID [2]
0
0
CO39722
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced BRAFV600 Wild-type Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cobimetinib
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Pembrolizumab
Experimental: Cobimetinib and Atezolizumab - Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
Active comparator: Pembrolizumab - Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
Treatment: Drugs: Cobimetinib
Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
Treatment: Drugs: Atezolizumab
Atezolizumab 840 mg as IV infusion once in every 2 weeks.
Treatment: Drugs: Pembrolizumab
Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS) as Determined by the Independent Review Committee (IRC)
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by an IRC according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.
Query!
Timepoint [1]
0
0
Every 8 weeks (wks) from Day (D) 1 of Cycle (C) 1 through approximately 16 months
Query!
Secondary outcome [1]
0
0
PFS as Determined by the Investigator
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.
Query!
Timepoint [1]
0
0
Every 8 weeks (wks) from Day (D) 1 of Cycle (C) 1 through approximately 16 months
Query!
Secondary outcome [2]
0
0
Objective Response as Determined by the Investigator
Query!
Assessment method [2]
0
0
Objective response rate is defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions \>/=4 weeks apart, as determined by the investigator through the use of RECIST v1.1. For target lesion, CR: the disappearance of all target lesions, any pathological lymph nodes must have a reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. For non-target lesion, CR: the disappearance of all non-target lesions and (if applicable) normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis).
Query!
Timepoint [2]
0
0
Every 8 weeks (wks) from Day (D) 1 of Cycle (C) 1 through approximately 16 months
Query!
Secondary outcome [3]
0
0
Objective Response as Determined by IRC
Query!
Assessment method [3]
0
0
Objective response, defined as a complete response or partial response on two consecutive occasions =4 weeks apart, as determined by IRC according to RECIST v1.1
Query!
Timepoint [3]
0
0
Every 8 weeks (wks) from Day (D) 1 of Cycle (C) 1 through approximately 16 months
Query!
Secondary outcome [4]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [4]
0
0
DCR is defined as the proportion of participants with a complete response, a partial response, or stable disease at 16 weeks. For target lesion, CR: the disappearance of all target lesions, any pathological lymph nodes must have a reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. For non-target lesion, CR: the disappearance of all non-target lesions and (if applicable) normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). Stable disease (SD): neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD.
Query!
Timepoint [4]
0
0
Week 16
Query!
Secondary outcome [5]
0
0
Overall Survival (OS)
Query!
Assessment method [5]
0
0
OS is defined as the time from randomization to death from any cause.
Query!
Timepoint [5]
0
0
From randomization up to approximately 3 years
Query!
Secondary outcome [6]
0
0
Duration of Objective Response Determined by the IRC
Query!
Assessment method [6]
0
0
Duration of objective response, defined as the time from the first occurrence of a documented objective response to disease progression, as determined by an IRC according to RECIST v1.1, or death from any cause, whichever occurs first.
Query!
Timepoint [6]
0
0
Every 8 weeks (wks) from Day (D) 1 of Cycle (C) 1 through approximately 16 months
Query!
Secondary outcome [7]
0
0
Duration of Objective Response Determined by the Investigator
Query!
Assessment method [7]
0
0
Duration of objective response is defined as the time from the first occurrence of a documented objective response to disease progression, as determined by the investigator through use of RECIST v1.1, or death from any cause, whichever occurs first.
Query!
Timepoint [7]
0
0
Up to 3 years
Query!
Secondary outcome [8]
0
0
Two-year Landmark Survival
Query!
Assessment method [8]
0
0
Two-year landmark survival is defined as the rate of survival at 2 years. Two-year landmark survival is defined as the rate of survival at 2 years and was calculated using Kaplan-Meier analysis, which is commonly used to estimate the probability of an event at time 't.'
Query!
Timepoint [8]
0
0
At 2 years
Query!
Secondary outcome [9]
0
0
Change From Baseline in Health-related Quality of Life (HRQoL) Scores
Query!
Assessment method [9]
0
0
HRQoL scores are assessed through global health status (GHS)/ quality of life (QoL) subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30). These are based on questions 29 and 30 of the EORTC QLQ-C30. These questions on global health status/QoL scale are coded on 7-point scale (1=very poor to 7=excellent). Raw scores will be linearly transformed to obtain the score ranging from 0 to 100, where higher score represents a higher ("better") level of functioning.
Query!
Timepoint [9]
0
0
Up to approximately 16 months. Follow up is reported at weeks after participant treatment discontinuation, which could occur at any time during the study. Total time frame does not exceed 16 months.
Query!
Secondary outcome [10]
0
0
Number of Participants With Adverse Events (AEs)
Query!
Assessment method [10]
0
0
An adverse event is any untoward medical occurrence in a patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Query!
Timepoint [10]
0
0
Up to approximately 16 months
Query!
Secondary outcome [11]
0
0
Number of Participants With Abnormal Vital Signs
Query!
Assessment method [11]
0
0
Vital signs will include temperature, pulse rate, respiratory rate, and systolic and diastolic blood pressure.
Query!
Timepoint [11]
0
0
From baseline up to approximately 3 years
Query!
Secondary outcome [12]
0
0
Number of Participants With Laboratory Abnormalities
Query!
Assessment method [12]
0
0
Participants with laboratory abnormalities (values outside of a defined range) will be reported.
Query!
Timepoint [12]
0
0
Up to approximately 16 months
Query!
Secondary outcome [13]
0
0
Plasma Concentration of Cobimetinib
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Days 1 and 15 of Cycle 1
Query!
Secondary outcome [14]
0
0
Serum Concentration of Atezolizumab
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Day 1 of Cycles 1, 2, and 3
Query!
Secondary outcome [15]
0
0
Percentage of Participants With Anti-drug Antibodies (ADAs)
Query!
Assessment method [15]
0
0
Participants with ADAs during the study relative to the prevalence of ADAs at baseline will be reported.
Query!
Timepoint [15]
0
0
Day 1 of Cycle 1, 2, 3 and 30 days after treatment discontinuation
Query!
Eligibility
Key inclusion criteria
Disease-Specific Inclusion Criteria
* Histologically confirmed locally advanced and unresectable or metastatic melanoma
* Naive to prior systemic anti-cancer therapy for melanoma
* Documentation of BRAFV600 wild-type status in melanoma tumor tissue through use of a clinical mutation test approved by the local health authority
* A representative, formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 20 slides containing unstained, freshly cut, serial sections must be submitted along with an associated pathology report prior to study entry. If 20 slides are not available or the tissue block is not of sufficient size, the patient may still be eligible for the study, after discussion with and approval by the Medical Monitor
* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
* Age >=18 years at time of signing Informed Consent Form
* Ability to comply with the study protocol, in the investigator's judgment
* Histologically or cytologically confirmed BRAFV600 wild-type melanoma
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Life expectancy >=3 months
* Adequate hematologic and end-organ function
* For women of childbearing potential: agreement to remain abstinent or use at least two forms of effective contraceptive with a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of cobimetinib and at least 5 months after the last dose of atezolizumab or pembrolizumab
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures (e.g. condom), and agreement to refrain from donating sperm, for at least 3 months after the last dose of cobimetinib
* Willingness and ability of patients to report selected study outcomes (e.g., GHS and HRQoL) using an electronic device or paper backup questionnaires.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
General Exclusion Criteria
* Inability to swallow medications
* Malabsorption condition that would alter the absorption of orally administered medications
* Pregnancy, breastfeeding, or intention of becoming pregnant during the study
* History of severe hypersensitivity reactions to components of the cobimetinib, atezolizumab, or pembrolizumab formulations
* Current or recent treatment with therapeutic antibiotics, live attenuated vaccines or systemic immunostimulatory/immunosuppresive medication
* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study Cancer-Related Exclusion Criteria
* Ocular melanoma
* Major surgery or radiotherapy within 21 days prior to Day 1 of Cycle 1 or anticipation of needing such procedure while receiving study treatment
* Uncontrolled tumor-related pain
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days
* Active or untreated central nervous system (CNS) metastases Exclusions Related to Cardiovascular Disease
* Unstable angina, new-onset angina within last 3 months, myocardial infarction within the last 6 months prior to Day 1 of Cycle 1, or current congestive heart failure classified as New York Heart Association Class II or higher
* Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or <50%, whichever is lower
* Poorly controlled hypertension, defined as sustained, uncontrolled, non-episodic baseline hypertension consistently above 159/99 mmHg despite optimal medical management
* History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third degree heart block, or evidence of prior myocardial infarction Exclusions Related to Infections
* HIV infection
* Active tuberculosis infection
* Severe infections within 4 weeks prior to Day 1 of Cycle 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
* Signs or symptoms of clinically relevant infection within 2 weeks prior to Day 1 of Cycle 1
* Treatment with oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1
* Active or chronic viral hepatitis B or C infection Exclusions Related to Ocular Disease
* Known risk factors for ocular toxicity Exclusions Related to Autoimmune Conditions and Immunomodulatory Drugs
* Active or history of autoimmune disease or immune deficiency
* Prior allogeneic stem cell or solid organ transplantation
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
* Treatment with systemic immunosuppressive medications within 2 weeks prior to Day 1, Cycle 1 Exclusions Related to Other Medical Conditions or Medications
* Active malignancy (other than melanoma) or a prior malignancy within the past 3 years
* Any Grade >=3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1
* History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months prior to Day 1
* Proteinuria >3.5 gm/24 hr
* Consumption of foods, supplements, or drugs that are strong or moderate CYP3A4 enzyme inducers or inhibitors at least 7 days prior to Day 1 of Cycle 1 and during study treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/12/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/02/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
446
Query!
Recruitment in Australia
Recruitment state(s)
QLD,TAS,WA
Query!
Recruitment hospital [1]
0
0
Cairns Base Hospital - Cairns
Query!
Recruitment hospital [2]
0
0
Townsville General Hospital - Douglas
Query!
Recruitment hospital [3]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [4]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [5]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
4870 - Cairns
Query!
Recruitment postcode(s) [2]
0
0
4184 - Douglas
Query!
Recruitment postcode(s) [3]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [5]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Hampshire
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
North Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
West Virginia
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Bruxelles
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Kortrijk
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Leuven
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
RJ
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
RS
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Bobigny
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Bordeaux
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Dijon
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Grenoble
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Le Mans
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Lille
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Marseille
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Nantes
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Nice cedex 3
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Paris
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Reims
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Rennes
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Rouen
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Toulouse
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Villejuif
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Dresden
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Erfurt
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Essen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Frankfurt
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Gera
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hannover
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Kiel
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Mainz
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Mannheim
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Minden
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
München
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Münster
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Tübingen
Query!
Country [48]
0
0
Greece
Query!
State/province [48]
0
0
Athens
Query!
Country [49]
0
0
Greece
Query!
State/province [49]
0
0
Pireaus
Query!
Country [50]
0
0
Greece
Query!
State/province [50]
0
0
Thessaloniki
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Budapest
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Pecs
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Szeged
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Campania
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Emilia-Romagna
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Lazio
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Liguria
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Lombardia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Piemonte
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Puglia
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Toscana
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Veneto
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Seoul
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Amsterdam
Query!
Country [65]
0
0
Netherlands
Query!
State/province [65]
0
0
Breda
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Rotterdam
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Sittard-Geleen
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Gdansk
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Lublin
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Poznan
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Szczecin
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Warszawa
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Wroclaw
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Moskovskaja Oblast
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Moscow
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Saint-Petersburg
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
St Petersburg
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Barcelona
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Islas Baleares
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
LA Coruña
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
LAS Palmas
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Navarra
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Madrid
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Sevilla
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Valencia
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Zaragoza
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Bristol
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Edinburgh
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Leicester
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
London
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Stoke-On-Trent
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Swansea
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Truro
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03273153
Query!
Trial related presentations / publications
de Azevedo SJ, de Melo AC, Roberts L, Caro I, Xue C, Wainstein A. First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma. Pigment Cell Melanoma Res. 2021 Sep;34(5):973-977. doi: 10.1111/pcmr.12960. Epub 2021 Feb 15.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/53/NCT03273153/Prot_002.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/53/NCT03273153/SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03273153
Download to PDF